Compare Amgen, Inc. (AMGN) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Roundhill Magnificent Seven ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Roundhill Magnificent Seven ETF trades at $67.45. The key difference: Amgen, Inc. pays a 2.77% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals.
| AMGN | MAGS | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $70.94 |
52-Week Low | $271.18 | $55.39 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MAGS trades at $67.68, up 1.38% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF holds equal-weighted Magnificent Seven stocks, offering concentrated mega-cap tech exposure. Recent news highlights AI-driven volatility and debates over concentration risks versus growth potential, with the fund up 181% since launch but facing 2026 headwinds as AI profits outside tech remain uncertain.
Outlook hinges on AI adoption and interest rate trends, with small-cap rotation posing a risk. Opportunities include hyperscaler valuation compression and quarterly rebalancing. Key risks are overconcentration in tech, regulatory scrutiny, and macroeconomic shifts affecting growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
